Click Therapeutics is a technology company.
Click Therapeutics has raised $71.0M across 2 funding rounds.
Click Therapeutics has raised $71.0M in total across 2 funding rounds.
Click Therapeutics is a New York-based technology company founded in 2012 that develops, validates, and commercializes software as prescription medical treatments, known as digital therapeutics (DTx).[1][2] It builds FDA-regulated prescription mobile apps addressing unmet needs in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases, serving patients via smartphones with clinically proven, patient-centric solutions that combine cognitive, behavioral, and neuromodulatory mechanisms enhanced by AI and machine learning.[1][2] A key product is Rejoyn™, the first FDA-authorized DTx for adjunctive treatment of major depressive disorder symptoms, developed with Otsuka; the company also launched Click SE™ in 2024, pairing its platform with pharmacotherapy for software-enhanced drug therapies in pharma collaborations.[1] With 130 employees across four offices and recent Series C funding from Dassault Systèmes, Click shows strong growth momentum through clinical validations, brand refresh, and platform expansion.[1][2][4]
Click Therapeutics was founded in 2012 by David Benshoof Klein, who serves as CEO, with a focus on operating at the intersection of biology and technology to deliver prescription digital therapeutics.[1][2] The idea emerged from recognizing the potential of smartphone apps as regulated medical treatments, leveraging patient-centric design and AI to achieve superior engagement and outcomes for conditions like depression where traditional therapies fall short.[1][2] Early traction included robust clinical data generation and the 2024 FDA authorization of Rejoyn™ with Otsuka, marking a pivotal milestone as the first such DTx for major depressive disorder; this built on years of platform refinement, leading to the October 2024 launch of Click SE™ amid FDA guidance on software-pharmacotherapy combos.[1]
Click Therapeutics rides the digital therapeutics trend, merging biotech with software to make prescription treatments accessible via smartphones, amid rising demand for non-pharmacological or adjunctive options in chronic diseases.[1][2] Timing aligns with FDA's evolving PDURS guidance and pharma interest in combos, as seen in Rejoyn™ and Click SE™, fueling market growth in a sector projected to expand with AI personalization.[1][3] Favorable forces include post-pandemic telehealth adoption, AI advancements shortening development cycles, and investor backing like Dassault Systèmes' Series C for patient experience improvements.[1][4] Click influences the ecosystem by pioneering regulated DTx, validating software's medical role, and partnering with pharma to hybridize treatments, setting standards for scalable, data-driven healthcare tech.[1][2]
Click Therapeutics is poised to lead in software-enhanced drug therapies, with Click SE™ enabling deeper pharma integrations and AI optimizing outcomes across psychiatry to cardiometabolic areas.[1][3] Trends like AI-driven personalization, regulatory clarity, and hybrid bio-digital models will accelerate its pipeline, potentially yielding more FDA nods and global scale. Its influence may evolve from DTx innovator to ecosystem shaper, redefining care standards for unmet needs—just as its smartphone-delivered prescriptions already transform access for patients worldwide.[1][2]
Click Therapeutics has raised $71.0M in total across 2 funding rounds.
Click Therapeutics's investors include Eight Roads Ventures, Sanofi Ventures, Webtalk Ltd, Omega Funds.
Click Therapeutics has raised $71.0M across 2 funding rounds. Most recently, it raised $52.0M Series B in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $52.0M Series B | Eight Roads Ventures, Sanofi Ventures, Webtalk Ltd | |
| Oct 1, 2018 | $19.0M Series A | Omega Funds |